Biotech Trading Update Trevena Inc. (NASDAQ:TRVN), Tocca Life Holdings Inc (OTCMKTS:TLIF), Champions Oncology Inc. (NASDAQ: CSBR)
Trevena Inc. (NASDAQ:TRVN) is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics for G protein-coupled receptors. The company’s central nervous system product pipeline includes TRV130, a small molecule G protein-biased ligand at the mu-opioid receptor, which is in Phase 2 clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred, as well as TRV734, a small molecule G protein-biased ligand at the mu-opioid receptor that is in Phase 1 clinical trials for the treatment of moderate to severe acute and chronic pain. Over the past week, shares were up 76.9%, while year to date they also are up 76.9%. Shares of were trading at $10.76 on Friday’s close. The stock has a consensus analyst price target of $9.75 and a 52-week trading range of $3.80 to $11.94.
Tocca Life Holdings Inc (OTCMKTS:TLIF) expertise in the drug testing industry and manufacturing partners within US and China provide top quality products with OTC approval. All products will be tested and used in TLIF professional, sober living residences before they are marketed by TOCCA. They will have their own unique branding, are very accurate and have higher margins than the current drop ship protocol.
Product web sites
Three web sites each targeted to different sectors of the market place.
• https://www.buyatestkit.com – Home, family and individuals.
• http://www.buyadrugTest.com – Corporate, small to medium sized companies.
• https://drugtestkits.toccalife.com – Rehab centers, halfway houses, drug abuse centers.
The global drugs of abuse testing market was valued at $2.6 billion in 2012. The estimated market for drug testing is expected to exceed $3.4 billion globally by 2018 which makes our marketing strategy to set up and deploy three web sites very timely. We are strategically well placed to capitalize on this and sell a broad range of products into the marketplace at discounted prices whilst benefiting over 100% profit from each retail sale, eliminating marketing costs for our core business and maximizing the funnel down marketing to our core business of sober living residences with re-occurring revenues from clinical laboratory toxicology testing and safety.
The product range includes urine, oral saliva and on-contact tests. They produce rapid results and test from one to over fourteen different drugs in one test.
Champions Oncology Inc. (NASDAQ: CSBR) develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based on the implantation of human tumors in immune-deficient mice. Over the past week, shares were up 3.1%, while year to date they are up 16.6%. Shares were trading at $7.00 on Friday’s close. The 52-week trading range is $2.40 to $10.08.
Trevena Inc. (NASDAQ:TRVN)
Trevena Inc. (Trevena), incorporated on November 9, 2007, is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: TRV130, TRV734 and TRV027. TRV130 is a small molecule G protein biased ligand at the mu-opioid receptor that it is developing as a first-line treatment for patients experiencing moderate to severe acute pain where IV administration is preferred. TRV734 is a small molecule G protein biased ligand at the mu-opioid receptor that it is developing as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R), inhibiting G protein signaling and activating b-arrestin signaling.
TRV130
The Company is developing TRV130 as a first-line treatment for patients experiencing moderate to severe pain where IV administration is preferred. TRV130 activates the mu-opioid receptor G protein pathway, which in preclinical studies was associated with analgesia, and inhibits the b-arrestin pathway at the same receptor, which in preclinical studies was associated with limiting opioid analgesia and with promoting opioid-induced respiratory depression and constipation. TRV130 is in Phase II clinical trials.
TRV734
The Company is developing TRV734 as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Like TRV130 TRV734 takes advantage of a well-established mechanism of pain relief by targeting the mu-opioid receptor but does so with enhanced selectivity for the G protein signaling pathway. The Company has completed both a Phase I single ascending dose clinical trial and a Phase I multiple ascending dose clinical study and reported positive results from these studies in June 2014 and February 2015, respectively.
TRV027
The Company is developing TRV027 for the treatment of acute heart failure (AHF). The Company is enrolling patients in a Phase II (b) clinical trial to evaluate the safety and efficacy of TRV027 in AHF.
TRV250
The Company has identified a new product candidate, TRV250, from its preclinical delta-opioid receptor program focused on central nervous system (CNS). TRV250 is a small molecule G protein biased ligand of the delta-opioid receptor.
The post Biotech Trading Update Trevena Inc. (NASDAQ:TRVN), Champions Oncology Inc. (NASDAQ: CSBR) appeared first on Live Trading News.